基于TLR4信号通路的中药抗肝脏疾病作用研究进展

被引：32

作者：

农汝楠 ^{[1
]}

王竟静 ^{[1
]}

吴燕春 ^{[2
]}

刘舒凌 ^{[2
]}

刘偲翔 ^{[1
]}

周至品 ^{[1
]}

机构：

[1] 广西中医药大学附属瑞康医院

[2] 广西中医药大学药学院

来源：

中国实验方剂学杂志 | 2019年 / 25卷 / 16期

关键词：

中药; Toll样受体4 (TLR4); 抗肝脏疾病; 研究进展;

D O I：

暂无

中图分类号：

R285.5 [中药实验药理];

学科分类号：

100806 [中药药理学];

摘要：

肝脏疾病是发生在肝脏的所有疾病的总称。近年来中药在治疗肝脏疾病中有一定优势,其实验研究作用显著或临床应用疗效较好,不良反应较少,呈现了广阔的前景。Toll样受体4(TLR4)信号通路与肝脏疾病息息相关,其抑制机制是通过TLR4介导的信号通路活化核转录因子-κB(NF-κB),抑制白细胞介素-1β(IL-1β),白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)等炎症因子的分泌,抑制肝细胞的炎症损伤,进一步抑制了IL-1β,IL-6,TNF-α等对肝星状细胞(HSC)等细胞的激活,其阻断TRL4通路的方式为①抑制TLR4的表达;②抑制TLR4二聚体化;③阻断胞内信号转导,通过作用于衔接蛋白,作用于激酶IL-1受体相关激酶(IRAKs),作用于去泛素化酶锌指蛋白A20(TLRAFst)。通过这几个方面阻断TRL4通路,抑制炎症反应发生,达到抗肝脏疾病的作用。因此,抑制或增强TLR4信号通路或针对TLR4信号通路中某些环节进行干预成为肝病治疗的新策略。目前TLR4信号通路成为中药抗肝脏疾病的靶点之一。本文对近年中药抗TLR4信号通路活化,通过中药单体及有效部位、中药提取物、中药复方等发挥抗肝脏疾病作用的文献进行整理,为下一步中西医治疗肝脏疾病提供重要的指导意义和方向。

引用

页码：201 / 212

页数：12

共 56 条

[1]

Protective effects of ginsenoside Rg1 against lipopolysaccharide/ d -galactosamine-induced acute liver injury in mice through inhibiting toll-like receptor 4 signaling pathway.[J].Chenqing Ning;Xiaoguang Gao;Changyuan Wang;Xiaokui Huo;Zhihao Liu;Huijun Sun;Xiaobo Yang;Pengyuan Sun;Xiaodong Ma;Qiang Meng;Kexin Liu.International Immunopharmacology.2018,

[2]

Andrographolide Ameliorates Liver Fibrosis in Mice: Involvement of TLR4/NF- κ B and TGF- β 1/Smad2 Signaling Pathways.[J].Liteng Lin;Rui Li;Mingyue Cai;Jingjun Huang;Wensou Huang;Yongjian Guo;Liuhong Yang;Guizhi Yang;Tian Lan;Kangshun Zhu;Kum Kum Khanna.Oxidative Medicine and Cellular Longevity.2018,

[3]

Lycium barbarum polysaccharides improve CCl 4 -induced liver fibrosis; inflammatory response and TLRs/NF-kB signaling pathway expression in wistar rats.[J].Fang Gan;Qing Liu;Yunhuan Liu;Da Huang;Cuiling Pan;Suquan Song;Kehe Huang.Life Sciences.2018,

[4]

Polydatin Protects Rat Liver against Ethanol-Induced Injury: Involvement of CYP2E1/ROS/Nrf2 and TLR4/NF- κ B p65 Pathway.[J].Qiong-Hui Huang;Lie-Qiang Xu;Yu-Hong Liu;Jia-Zhen Wu;Xue Wu;Xiao-Ping Lai;Yu-Cui Li;Zi-Ren Su;Jian-Nan Chen;You-Liang Xie;Raffaele Capasso.Evidence-Based Complementary and Alternative Medi.2017,

[5]

Protective effects of morin on lipopolysaccharide/ d -galactosamine-induced acute liver injury by inhibiting TLR4/NF-κB and activating Nrf2/HO-1 signaling pathways.[J].Ye Tian;Zheng Li;Bingyu Shen;Qiaoling Zhang;Haihua Feng.International Immunopharmacology.2017,

[6]

Chlorogenic acid ameliorated concanavalin A-induced hepatitis by suppression of Toll-like receptor 4 signaling in mice.[J].Yinglin Yuan;Xia Gong;Li Zhang;Rong Jiang;Junxia Yang;Bin Wang;Jingyuan Wan.International Immunopharmacology.2017,

[7]

Oxymatrine attenuates CCl 4 -induced hepatic fibrosis via modulation of TLR4-dependent inflammatory and TGF-β1 signaling pathways.[J].Hong-wei Zhao;Zhen-fang Zhang;Xuan Chai;Guang-quan Li;He-rong Cui;Hong-bo Wang;Ya-kun Meng;Hui-min Liu;Jia-bo Wang;Rui-sheng Li;Zhao-fang Bai;Xiao-he Xiao.International Immunopharmacology.2016,

[8]

Dioscin reduces lipopolysaccharide-induced inflammatory liver injury via regulating TLR4/MyD88 signal pathway.[J].Hong Yao;Changsheng Hu;Lianhong Yin;Xufeng Tao;Lina Xu;Yan Qi;Xu Han;Youwei Xu;Yanyan Zhao;Changyuan Wang;Jinyong Peng.International Immunopharmacology.2016,

[9]

Resveratrol preconditioning protects hepatocytes against hepatic ischemia reperfusion injury via Toll-like receptor 4/nuclear factor-κB signaling pathway in vitro and in vivo.[J].Diao He;Zhen Guo;Jun-Liang Pu;Dao-Feng Zheng;Xu-Fu Wei;Rui Liu;Cheng-Yong Tang;Zhong-Jun Wu.International Immunopharmacology.2016,

[10]

Protective effect of Rabdosia amethystoides (Benth) Hara extract on acute liver injury induced by Concanavalin A in mice through inhibition of TLR4-NF-κB signaling pathway.[J].Ke-Feng Zhai;Hong Duan;Wen-Gen Cao;Gui-Zhen Gao;Ling-Ling Shan;Xue-Mei Fang;Liang Zhao.Journal of Pharmacological Sciences.2015,

← 1 2 3 4 5 6 →